Kato Hiroaki, Kato Noriyuki, Ouchi Takafumi, Higashigawa Takatoshi, Nakajima Ken, Chino Shuji, Ito Hisato, Tokui Toshiya, Mizumoto Toru, Oue Kensuke, Ichikawa Yasutaka, Sakuma Hajime
Department of Radiology, Mie University Hospital, Tsu, Mie, Japan.
Department of Radiology, Mie University Hospital, Tsu, Mie, Japan.
J Vasc Interv Radiol. 2025 Jan;36(1):139-145. doi: 10.1016/j.jvir.2024.10.012. Epub 2024 Oct 19.
To investigate the effectiveness and safety of thoracic endovascular aortic repair (TEVAR) for infectious aortic diseases.
Patients who underwent TEVAR for infectious aortic diseases including infected thoracic aortic aneurysm, aortobronchial fistula (ABF), and aortoenteric fistula from December 2011 to October 2022 at 4 institutions were retrospectively studied. The primary outcome of the study was overall survival, whereas the secondary outcome was comprehensive adverse events. Comprehensive adverse events were defined as a combination of deaths, aortic events, and infectious adverse events.
A total of 28 patients were included in the analysis, with 13 patients having infected thoracic aortic aneurysms, 12 ABFs, and 3 aortoenteric fistulae. Seven patients (25%) underwent additional procedures (abscess drainage, 6 cases; total esophagectomy, 1 case). The mean follow-up period was 30.0 months (SD ± 33.9). The 1-year and 5-year survival rates were 85.7% and 67.9%, respectively. The 1-year and 5-year aorta-related complication-free survival rates were 64.3% and 42.9%, respectively. On univariate analysis, the presence of an ABF was associated with a higher risk of comprehensive adverse events (odds ratio = 11; P = .038).
TEVAR might be a promising treatment for infectious thoracic aortic diseases. Among the infectious pathologies, ABF was considered ominous in terms of late outcomes.
